Terns Pharmaceuticals, Inc. reported a loss of -$24.09 million in the second quarter. The bottom line was -$0.26 per share, compared to -$0.31 per share last year. Earnings on a GAAP basis were -$24.09 million, down from -$22.73 million last year, with EPS at -$0.26 compared to -$0.31 last year.

Read more at Nasdaq.: Terns Pharmaceuticals, Inc. Loss At -$24.09 Mln In Q2